Interestingly, by analyzing large human tumor cohorts profiled by The Cancer Genome Atlas30 (TCGA), we found that FOXO1 was downregulated in the vast majority of human breast, prostate, and pancreatic tumors (Fig. 4e) despite being only rarely target of genetic alterations in these tumor types: ~8% in prostate, <2% in breast, and never in pancreatic cancer (source cBioPortal31). Here, FOXO1 is linked to familial pancreatic carcinoma.